Regulation - North America, Pricing


Current filters:

North AmericaPricing

Popular Filters

US FDA approval for Gilead's hepatitis C drug Sovaldi

US FDA approval for Gilead's hepatitis C drug Sovaldi


US antiviral biotech specialist Gilead Sciences says that the Food and Drug Administration has approved…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingRegulationsofosbuvirSovaldi

Unnecessary drug regulations hiking Rx prices in USA: NCPA Study


As drug coverage increases as a result of expanded health insurance and Medicaid coverage under the USA's…

BiotechnologyNorth AmericaPharmaceuticalPricingRegulation

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status


In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

US patients get faster access to more cancer drugs than Europeans, says Tufts


Cancer patients in the USA get faster access to more oncology drugs to treat their disease than patients…

BiotechnologyEuropeHealthcareNorth AmericaOncologyPharmaceuticalPricingRegulation

Gilead files elvitegravir and cobicistat with FDA; AHF plea on Quad pricing


US biotech firm Gilead Sciences (Nasdaq: GILD), world's largest maker of HIV drugs, has submitted a New…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaPricingQuadRegulation

High expectations for new US biosimilars following FDA guidance documents


In light of the upcoming FDA guidance for biosimilar approval, Novation, health care supply chain expertise…

BiotechnologyGenericsNorth AmericaPricingRegulation

Bayer's Xarelto reimbursement backed in Canada; EMA concludes Yvidually arbitration


The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR),…

BayerCardio-vascularEuropeNorth AmericaPharmaceuticalPricingRegulationReproductiveXareltoYvidually

Affymax and Takeda get special Medicare code for Omontys


USA-based Affymax (Nasdaq: AFFY) and the US subsidiary of Japanese drug major Takeda Pharmaceuticals…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontysOncologypeginesatidePharmaceuticalPricingRegulationTakeda Pharmaceuticals

Canadian patients wait two and a half years for new drug access


As a result of government bureaucracies to approve new prescription drugs for public use, Canadians are…

North AmericaPharmaceuticalPoliticsPricingRegulation

Back to top